NicOx' Naproxcinod Shows Differentiated 24-Hour Blood Pressure Profile After 13 Weeks Treatment
Posted on: Friday, 19 December 2008, 06:00 CST
SOPHIA ANTIPOLIS,
Naproxcinod is the most advanced compound in the new Cyclooxygenase-Inhibiting Nitric Oxide Donator (CINOD) class. COX-2 inhibitors and traditional NSAIDs, such as ibuprofen and naproxen, are widely used as symptomatic treatments for OA. However, there is increasing concern in the medical community over their tendency to raise blood pressure and destabilize previously controlled hypertensive patients.
"The results from the 112 study demonstrate important differential effects of naproxcinod's 24-hour ABPM profile at 13 weeks, compared to ibuprofen and naproxen, two of the most commonly used NSAIDs," continued Professor White. "Both cardiovascular specialists and rheumatologists place great importance on the additional level of detail provided by the ABPM technique, a method which has become a gold standard in blood pressure measurement in clinical trials and practice. Furthermore, these new results should provide support to the findings from the pooled blood pressure data from the phase 3 program."
Naproxcinod showed positive efficacy results in a program of three pivotal phase 3 studies in OA patients (301, 302 and 303). Moreover, a pre-specified pooled analysis of the Office Blood Pressure Measurements (OBPMs) collected in 2,734 patients in these trials showed a significant reduction in SBP and diastolic blood pressure (DBP) for both doses of naproxcinod (375 and 750 mg bid) over the whole 13 week period, compared to naproxen 500 mg bid. NicOx plans to submit a New Drug Application (NDA) for naproxcinod to the US Food and Drug Administration (FDA) in mid-2009.
Both doses of naproxcinod showed a blood pressure reduction compared to naproxen and ibuprofen.
The 112 study was a 16-week clinical pharmacology trial, with a
double-blind, parallel group design, in which 299 OA patients with controlled
hypertension were enrolled at 60 clinical sites in
The 24-hour blood pressure monitoring was conducted at baseline and at week 13 using a validated ABPM device. The primary parameter was the mean 24-hour ambulatory SBP as measured by ABPM at week 13. Compared to naproxen 500 mg bid, naproxcinod 750 mg bid lowered SBP by 2.7 mmHg and DBP by 1.4 mmHg, in terms of the mean change from baseline at week 13. Naproxcinod 375 mg bid decreased SBP by 1.1 mmHg and DBP by 0.8 mmHg compared to naproxen 250 mg bid.
Naproxcinod 750 mg bid showed a 3.8 mmHg decrease in SBP and a 0.7 mmHg decrease in DBP compared to ibuprofen 600 mg tid, in terms of the mean change from baseline at week 13. Naproxcinod 375 mg bid showed a reduction in SBP of 4.2 mmHg and a reduction in DBP of 1.7 mmHg, compared to ibuprofen 600 mg tid.
Naproxcinod 375 mg bid was the treatment with the lowest percentage of patients experiencing at least one adverse event. There were no treatment-related serious adverse events in the study. Far more patients in the ibuprofen arm discontinued due to an adverse event compared to the other treatments.
The 112 results were consistent with those of previous studies and complete an extensive database describing naproxcinod's differentiated blood pressure profile.
The 112 study is the last in a program of three clinical pharmacology trials using the ABPM technique in a total of 548 subjects (see NOTE 2 on the 111 and 104 studies) and its results complete a detailed picture of naproxcinod's 24-hour blood pressure profile. In particular, the 112 results complement and confirm the recently reported data from the 111 study, as the 112 study tested corresponding doses of naproxcinod and naproxen in parallel groups, while the 111 study tested escalating doses of naproxcinod and naproxen. The extensive blood pressure data from these three ABPM studies suggest an effect of nitric oxide donation on blood pressure.
Further analyses on the 111 and 112 studies will form the basis of presentations at leading medical conferences and peer reviewed scientific publications during 2009 and 2010.
NOTE 1: In the 112 study, eligible patients were 40 years and older and had been suffering from osteoarthritis for at least three months, with at least one hip or knee involved. In addition to OA, all patients were diagnosed with controlled essential hypertension (i.e. systolic blood pressure (SBP) <140 mmHg and diastolic blood pressure (DBP) <90 mmHg) and were treated with stable doses of up to two different classes of antihypertensive agents. Patients with uncontrolled hypertension were excluded.
NOTE 2: In the 111 ABPM study, 118 OA patients with controlled hypertension were randomized on a 1:1 basis to receive naproxcinod or naproxen, with escalating doses every three weeks (375, 750 and a supra-therapeutic dose of 1125 mg bid for naproxcinod; 250, 500 and 750 mg bid for naproxen). Naproxcinod showed a statistically significant decrease in SBP of 3.8 mmHg (p=0.011) compared to naproxen over the whole study period. The 104 trial was a cross-over ABPM study in 131 hypertensive volunteers, which was designed to compare the 24-hour blood pressure profiles of naproxcinod 750 mg bid and naproxen 500 mg bid following two weeks of administration.
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.
Resources are focused on the development and pre-commercialization activities for naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents for the treatment of the signs and symptoms of osteoarthritis. Naproxcinod has completed three pivotal phase 3 studies with positive results and the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) is projected for mid-2009.
Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, widespread eye diseases and Chronic Obstructive Pulmonary Disease (COPD).
NicOx S.A. is headquartered in
This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of NicOx S.A. to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference filed with the AMF, which is available on the AMF website ( http://www.amf-france.org) or on NicOx S.A.'s website (http://www.nicox.com).
SOURCE NicOx
Source: PR Newswire
Related Articles
- Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study
- New Head-to-Head Study Comparing LEXIVA(R) and Atazanavir Show Similar Efficacy and Lipid Changes
- A Major Study Compares Direct Blood Volume Measurement Using the BVA-100 With the BNP Test for Managing Fluid Therapy in the Intensive Care Unit
- The Latest Head-to-Head Clinical Study Comparing the Risk of CIN Between Two Contrast Agents Used in CE-MDCT Examinations Was Published in Investigative Radiology
- New Data Show COREG CR (TM) Reduced Blood Pressure in Patients With Essential Hypertension
- SinoFresh Reports Patient Case Study: Allergic Fungal Rhinosinusitis in Adult Male With History of Sinus Conditions
- MedImmune Completes Enrollment in Phase 3 Study Comparing Numax(TM) to Synagis(R)
- Genentech Stops Enrolling Patients in Study
- Doctors Support Generics, but Feel Pressure From Patients
- Biogen Idec and Elan Announce Head-to-Head Study Comparing Safety and Efficacy of TYSABRI-R- to Rebif-R-
 |
 |
User Comments (0)
RSS Feeds